Kenneth Carleton Frazier (born December 17, 1954) is an American business executive. He is executive chairman and former CEO of the pharmaceutical company Merck & Co. (known as MSD outside of North America). After joining Merck & Co. as general counsel, he directed the company's defense against litigation over the anti-inflammatory drug Vioxx.

Feb 4, 2021 · KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Kenneth C. Frazier, chairman and chief executive officer, will retire as CEO, effective June 30, 2021.

P. Roy Vagelos transformed Merck during his tenure as CEO and Chairman from 1985 to 1995. Under his leadership, the company created breakthrough drugs like Mevacor for cholesterol control, Mectizan for river blindness, and an improved MMR vaccine.

Jun 12, 2023 · Former CEO and executive chairman of Merck, Ken Frazier, offers candid reflections on how crises tested his commitment to values—both Merck’s and his own.

Oct 26, 2022 · Rob Davis is chief executive officer and president of Merck. Previously, Rob served as Merck’s president, responsible for the company’s operating divisions — Human Health, Animal Health, Manufacturing and Merck Research Laboratories.

Nov 28, 2023 · Those credentials alone would have more than justified former Merck & Co. CEO Kenneth Frazier's selection as a recipient of one of The American Lawyer's 2023 Lifetime Achievement Awards.

Kenneth Carleton Frazier (born December 17, 1954) is an American business executive that served as the President and CEO of American multinational pharmaceutical company Merck & Co. from 2011 to 2021. He is the first African-American to lead a major pharmaceutical company.

Feb 4, 2021 · Ken Frazier, who has been Merck & Co.’s chief executive since 2011, will retire June 30, the New Jersey pharma said Thursday. He will continue to serve as executive chairman for a transition ...

Feb 4, 2021 · Merck’s outspoken chairman and CEO, Ken Frazier, is retiring after almost 30 years at the drugmaker, the company announced Thursday. Frazier, 66, will be succeeded on June 30 by CFO Robert...

Nov 28, 2022 · K en Frazier, the former chief executive of Merck, has been the preeminent pharmaceutical CEO of his era. He is also likely the most prominent CEO to have spoken out against the former...